Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,622 signal articles · 318 in last 24h · 112,499 total before filter · latest 42m ago
318last 24h
2128last 7d
377● bullish (7d)
180● bearish (7d)
204publishers
AllMacro300Earnings1200M&A92Regulatory23Product13Analyst20
✕ clear all filtersticker: CVSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Pharmacy giant closes more stores across U.S. in 2026
TheStreet1d agoneutral
Pharmacy giant closes more stores across U.S. in 2026

After closing hundreds of locations in recent years, a pharmacy giant is continuing to shrink its retail footprint, with more stores disappearing from communities across the U.S. The latest closures come as the chain works to reshape its business and focus on locations it believes have a stronger ...

Fluent Q2 Earnings Call Highlights
MarketBeat2d agoneutral
Fluent Q2 Earnings Call Highlights

Fluent (NASDAQ:FLNT) reported second-quarter 2026 revenue growth as its Commerce Media Solutions business expanded sharply and became a larger share of the company’s overall mix. Management said the quarter marked a milestone in the company’s strategic shift toward commerce media, while maintaining

Healthcare giant slashes key consultation fee to beat rivals
TheStreet5d agobullish
Healthcare giant slashes key consultation fee to beat rivals

CVS Health (CVS) is targeting the earliest point in a customer's weight-loss drug decision: the first consultation. On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee. That is the lowest sticker price in the ...

CVS Health (CVS) Is Down 8.6% After Raising 2026 Guidance And Expanding GLP-1 Tie-Up With Lilly – Has The Bull Case Changed?
Simply Wall St.6d agoneutral
CVS Health (CVS) Is Down 8.6% After Raising 2026 Guidance And Expanding GLP-1 Tie-Up With Lilly – Has The Bull Case Changed?

In early August 2026, CVS Health reported second-quarter results showing higher sales of US$35,117 million and revenue of US$106.10 billion, alongside net income of US$2,979 million and materially higher earnings per share versus a year earlier. On the same day, CVS Health also raised its 2026 earnings guidance and expanded its GLP-1 weight management offering through a new collaboration with Eli Lilly, underscoring how integrated pharmacy, insurance and care-delivery assets can be combined...

CVS Health (CVS) Stock Gets Fair Value Bump As Analysts Turn More Constructive
Simply Wall St.6d agoneutral
CVS Health (CVS) Stock Gets Fair Value Bump As Analysts Turn More Constructive

The fair value estimate for CVS Health has shifted from US$111.92 to US$114.88, signaling a modest reset in where analysts think the stock could be worth over time. This change lines up with recent research that leans constructive on CVS Health ahead of upcoming earnings, while still calling out execution and policy risks that could affect how closely the stock trades to that mark. As you read on, you will see how to track this evolving story and what to watch as the narrative around CVS...

CVS Health Q2 Earnings Call Highlights
MarketBeat6d agoneutral
CVS Health Q2 Earnings Call Highlights

CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per share and operating cash flow. Chair and Chief Executive Officer David Joyner said the company gener

Eli Lilly is treating nearly 10% of US obesity population with GLP-1s: CFO
Yahoo Finance Video7d agoneutralVIDEO
Eli Lilly is treating nearly 10% of US obesity population with GLP-1s: CFO

After the company reported second quarter earnings and raised its full-year sales guidance, Eli Lilly (LLY) CFO Lucas Montarce outlines the expansion opportunities that the pharmaceutical giant is seeing in its GLP-1 category, specifically the introduction of oral weight-loss drugs to the market.

CVS Health tops second-quarter estimates, raises full-year profit outlook
Proactive7d agobullish
CVS Health tops second-quarter estimates, raises full-year profit outlook

CVS Health Corp (NYSE:CVS) reported second-quarter revenue and profit that beat Wall Street estimates on Wednesday, and raised its full-year adjusted earnings guidance, though cautious guidance pressured shares. Revenue rose 7.3% year-over-year to $106.1 billion, above analyst estimates of...